About
Applied Immune Technologies (AIT) is a drug development company specializing in T-cell-receptor-like (TCRL) antibodies for therapeutic and diagnostic applications in a variety of cancer, viral, and autoimmune diseases. The company also focuses on the identification and validation of novel therapeutic targets. AIT's core technology platforms encompass the identification and validation of novel MHC-based targets, as well as the development of therapeutic human recombinant TCRL antibodies with the ability to bind with these intracellular peptide/MHC complexes with the specificity of cytotoxic T-cell killer cells. AIT's technologies have the potentialto drive a pipeline of therapeutic TCRL antibodies for intracellularly derived, disease-specific targets that normally are not accessible to conventional antibodies. TCRL antibodies also have diagnostic applications in vaccine design, validation, and monitoring, as well as analysis of antigen presentation in diseases.
Funding history · 1 round · $4.4M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the primary focus of Applied Immune Technologies (AIT)?
- Applied Immune Technologies (AIT) is a drug development company specializing in T-cell-receptor-like (TCRL) antibodies for therapeutic and diagnostic applications in various cancer, viral, and autoimmune diseases.
- When was Applied Immune Technologies founded?
- Applied Immune Technologies was founded in February 2006.
- What was the status of Applied Immune Technologies as of January 2016?
- In January 2016, Applied Immune Technologies was acquired by Adicet Bio and subsequently became inactive.
- What was the total amount of funding raised by Applied Immune Technologies?
- Applied Immune Technologies raised a total of $4.4 million USD. For a full financing history, please refer to startupim.
- Which investor participated in Applied Immune Technologies' Series A funding round?
- Pontifax was an investor in Applied Immune Technologies' Series A funding round, which occurred in April 2010.
- Did Applied Immune Technologies receive any grants?
- Yes, Applied Immune Technologies received a grant of $400,000 USD from the IIA in July 2008.
- What is the employee count for Applied Immune Technologies?
- Applied Immune Technologies has an employee count in the range of 1-10.
- Who is a known founder of Applied Immune Technologies?
- Aya Yakobovitz, Ph.D. is a known founder of Applied Immune Technologies.